Clinical trials
Pulmonary Hypertension Due to Left Heart Disease clinical trials
Below are recruiting pulmonary hypertension due to left heart disease clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07292714RecruitingPhase 2
Testing 9MW1911 for people with moderate to severe COPD
This trial tests a new medication called 9MW1911 to see if it can help people with moderate to severe COPD who have had recent flare-ups. It is for current or former smokers ages 40 to 75 who are already on standard COPD treatments.
Chizhou, AnhuiAges 40–75 - NCT05442671Recruiting
Exercise coaching program for children with pulmonary hypertension
This trial tests whether a structured exercise program, done with remote support, is safe and helpful for children with pulmonary hypertension. It aims to improve how well kids function day-to-day while they stay on their usual PH medications.
Philadelphia, PennsylvaniaAges 8–18 - NCT07449325Recruiting
Heart sinus reducer for chest pain from small vessel disease
This trial tests a device placed in a heart vein (the coronary sinus) to improve blood flow and reduce chest pain in people with coronary microvascular dysfunction (small blood vessel disease). It aims to help those who still have symptoms despite taking heart medications.
New Haven, ConnecticutAges 18 years+ - NCT06491043RecruitingPhase 2
Stem cells for COPD: safety and early effectiveness study
This trial tests whether an infusion of donor stem cells can help people with moderate to severe COPD breathe easier. If you are a current or former smoker aged 40 to 80, your symptoms are stable, and your lung function meets specific targets, you may be able to join.
New Taipei CityAges 40–80 - NCT05519046Recruiting
Test a heart pacing treatment for Chagas-related heart failure
This study looks at a heart treatment called cardiac contractility modulation in people with Chagas heart disease who have moderate symptoms and weak heart pumping. It aims to see whether this therapy improves heart function and related outcomes in the right patients.
São Paulo, São PauloAges 18–75 - NCT06570473RecruitingPhase 2
RV failure treatment trial for pulmonary hypertension patients
This trial is testing two heart medications, empagliflozin and ranolazine, to see if they can improve right heart function in people with pulmonary hypertension and right ventricular failure. Participants will monitor their symptoms using a smartphone or tablet.
Calgary, AlbertaAges 18 years+ - NCT07130994Recruiting
Testing a new less invasive mitral valve replacement (SATURN)
This trial tests a new, less invasive device called the SATURN system to replace a severely leaky mitral heart valve without open-heart surgery. It is for people who are too high-risk for traditional surgery and are willing to take blood thinners.
Los Angeles, CaliforniaAges 18 years+ - NCT06194591Recruiting
Ultrasound treatment for high blood pressure with kidney disease
This trial tests a new ultrasound treatment on the kidney arteries to see if it can safely lower blood pressure in people with high blood pressure and chronic kidney disease. It may help avoid more invasive procedures.
Lausanne, Canton of VaudAges 18–82 - NCT06349174Recruiting
Lung valve treatment for severe COPD
This study tests whether placing tiny valves in the airways can help people with severe COPD breathe easier. It is for people who still have trouble breathing despite quitting smoking and completing pulmonary rehab.
Beijing, Beijing MunicipalityAges 40–85 - NCT02781922RecruitingPhase 3
Stem cell infusion for single-ventricle heart failure during surgery
This trial tests whether an infusion of heart stem/progenitor cells can improve outcomes for children with a single working heart chamber (single ventricle) who are scheduled for the next surgical stage (Glenn or Fontan). It may help the heart function after surgery, but participation depends on several heart, lung, brain, and overall health safety criteria.
KanagawaAges birth–6 years - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+ - NCT06317805RecruitingPhase 4
Three-medicine start vs. two oral pills for new PAH
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
LinzAges 18–70 - NCT06968962Recruiting
Starting PAH treatment: one drug first or two drugs together?
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
Hangzhou, ZhejiangAges 18–80 - NCT07701876Recruiting
Heart failure recovery markers study
This study looks for markers in the blood that can predict whether the heart's pumping function improves in people with chronic heart failure. It may help doctors understand which treatments work best for each person.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT05876000Recruiting
Heart pump study for very severe heart failure
This trial tests a left ventricular assist system (a mechanical heart pump for the left side of the heart) in people with very severe heart failure. It may help people who are too sick or not improving despite best available medical treatment.
GrazAges 18–75 - NCT07566494RecruitingPhase 1
Testing VAS-101 for sickle cell disease
This early-phase trial tests a new drug called VAS-101 for people with sickle cell disease. It aims to find a safe dose and see how the drug affects the body.
Bethesda, MarylandAges 18–90
Hear when a new Pulmonary Hypertension Due to Left Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary hypertension due to left heart disease?
- Yes. Clin2 currently lists 40 recruiting pulmonary hypertension due to left heart disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary hypertension due to left heart disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary hypertension due to left heart disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Chronic Thromboembolic Pulmonary Hypertension
- Hypoplastic Left Heart Syndrome
- Pulmonary Artery Hypertension
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Idiopathic Pulmonary Arterial Hypertension
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.